Document is current

Article History

Received: 25 March 2022

Accepted: 21 October 2022

First Online: 30 November 2022

Competing interests

: Janssen had a role in the conception or design of the work, acquisition of the data, analysis or interpretation of the data, preparation of the manuscript, and decision to publish. All authors were full-time employees of Janssen Pharmaceutical Companies of Johnson & Johnson at the time of the study and may own shares in Janssen Pharmaceutical Companies of Johnson & Johnson. Dr Van Effelterre reports ownership of shares in GlaxoSmithKline. All authors also report receiving grant support, paid to their institution, from the following: Biomedical Advanced Research and Development Authority (BARDA; Contract: HHSO100201700013C); the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH; Contracts: HHSN272200800056C, HHSN272201000006I, and HHSN272201200003I); and the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement number 115854 [EBOVAC1]). Additionally, this project has received funding from the Innovative Medicines Initiative 2 () Joint Undertaking under EBOVAC2 grant agreement No 115861; this Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Association (EFPIA). Dr Callendret is listed as an inventor on an international patent application (number PCT/US2015/048357) with publication number WO 2016/036955, entitled “Methods and compositions for inducing protective immunity against filovirus infection.” Dr Solforosi has participated in advisory boards for Abilita Bio, Inc. No other disclosures are reported.